Splice Bio
Barcelona
About Splice Bio
SpliceBio develops genetic medicines through its innovative Protein Splicing platform, focusing on gene therapies for genetic diseases. The company aims to address conditions caused by mutations in large genes, utilizing proprietary technologies to create novel treatment options. SpliceBio's pipeline includes programs targeting specific genetic disorders, such as Stargardt Disease. By leveraging its expertise in protein splicing, the company seeks to advance the field of gene therapy and improve patient outcomes. Through ongoing research and development, SpliceBio contributes to the understanding and treatment of complex genetic conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $193.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2025)
- Website: splice.bio
- Phone: +34934020456
Industries & Categories
Biotechnology, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/splice-bio-54934 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.